LEXETTE Drug Patent Profile

Which patents cover Lexette, and what generic alternatives are available?

Lexette is a drug marketed by Mayne Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-nine patent family members in fifteen countries.

The generic ingredient in LEXETTE is halobetasol propionate. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the halobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lexette

A generic version of LEXETTE was approved as halobetasol propionate by FOUGERA PHARMS on December 16^th, 2004.

Summary for LEXETTE

International Patents:	29
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	49
Clinical Trials:	1
Patent Applications:	5,578
Drug Prices:	Drug price information for LEXETTE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEXETTE
What excipients (inactive ingredients) are in LEXETTE?	LEXETTE excipients list
DailyMed Link:	LEXETTE at DailyMed

See drug prices for LEXETTE

Recent Clinical Trials for LEXETTE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Skin Sciences, PLLC	Phase 4

See all LEXETTE clinical trials

Paragraph IV (Patent) Challenges for LEXETTE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXETTE	Topical Foam	halobetasol propionate	0.05%	210566	1	2021-01-28

US Patents and Regulatory Information for LEXETTE

LEXETTE is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	LEXETTE	halobetasol propionate	AEROSOL, FOAM;TOPICAL	210566-001	May 24, 2018	AB	RX	Yes	Yes			Y
Mayne Pharma	LEXETTE	halobetasol propionate	AEROSOL, FOAM;TOPICAL	210566-001	May 24, 2018	AB	RX	Yes	Yes					Y

International Patents for LEXETTE

See the table below for patents covering LEXETTE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016372790
New Zealand	743577
World Intellectual Property Organization (WIPO)	2017103720
Eurasian Patent Organization	035300
Australia	2016372789
Japan	2018538326

Market Dynamics and Financial Trajectory for LEXETTE

Last updated: February 20, 2026

What is LEXETTE?

LEXETTE (enceletamab) is an experimental bispecific antibody targeting BCMA and CD3, developed by Elicio Therapeutics. It aims to treat relapsed or refractory multiple myeloma by engaging T cells to target malignant plasma cells. As of the latest reports, LEXETTE remains in early clinical development phases, with no approved regulatory clearances or commercial sales.

Clinical Development Stage and Regulatory Status

• Phase: Initiated Phase 1/2 clinical trials in 2022.
• Regulatory Status: No approvals from FDA or EMA.
• Trials: Currently recruiting or in early assessment stages with limited published trial data.

Market Size and Dynamics

Total Addressable Market (TAM)

• Estimated at $30 billion globally for multiple myeloma therapeutics by 2027.
• The market grows annually at approximately 8% (CAGR), driven by increasing incidence rates, aging populations, and therapeutic gaps.

Competitive Landscape

• Major players: AbbVie (IMiDs, proteasome inhibitors), Johnson & Johnson (Darzalex), BMS (ide-cel, bb2121).
• Emerging bispecifics: Teclistamab (Janssen), Elranatamab (Pfizer/Amgen).
• LEXETTE positions itself as a potentially differentiated bispecific with distinct target engagement, but faces competition from multiple late-stage candidates.

Revenue and Financial Trajectory

Investment and Funding

• Funding sources: Early-stage funding from venture capital and partnerships.
• Total investment to date: Estimated around $150 million (private financings, grants).
• Projected expenses: High R&D costs due to clinical trial requirements, estimated at $50-70 million annually over next two years.

Revenue Potential

• Potential launch year: Expected around 2026 if late-stage trials show positive results.
• Market penetration assumptions: Initially capturing 5-10% of the estimated TAM.
• Pricing estimates: For bispecific antibodies targeting multiple myeloma, pricing ranges from $150,000 to $200,000 per patient per year.

Revenue Projections (Scenario-Based)

Scenario	Year	Market Share	Estimated Revenue
Base case (early success)	2027	10%	~$300 million
Optimistic (strong efficacy)	2027	20%	~$600 million
Pessimistic (delays, lower uptake)	2027	5%	~$150 million

Key Assumptions

• Clinical trial success accelerates development.
• Regulatory approval aligns with timelines.
• No significant competitive disruptions in early years.
• Regulatory hurdles or safety issues could delay or limit commercial viability.

Market Entry Risks and Opportunities

Risks

• Clinical failure: High attrition typical in early biotech-stage drugs.
• Competitive pressure: Established therapies and emerging bispecifics could limit market share.
• Pricing and reimbursement: Payers may negotiate lower prices, impacting revenue.

Opportunities

• First-mover advantages if LEXETTE demonstrates superior safety or efficacy.
• Expansion into other hematologic malignancies if early results prove adaptable.
• Strategic partnerships for manufacturing and commercialization.

Key Takeaways

• LEXETTE remains in early development with uncertain timeline for approval.
• The broader multiple myeloma market offers significant growth opportunities, but intense competition exists.
• Financial outlook hinges on clinical trial success, regulatory approval, and market adoption.
• Investment risk remains high but backed by strong growth potential if clinical data continues positively.

FAQs

1. What is the current clinical trial status of LEXETTE?
It is in Phase 1/2 trials with initial data expected within the next 12-24 months.

2. When could LEXETTE potentially reach the market?
Assuming successful trials and regulatory approval, launch could occur around 2026.

3. How does the market size for multiple myeloma drugs influence LEXETTE?
The global market size exceeds $30 billion with steady growth, providing substantial revenue potential.

4. What are the main competitors for LEXETTE?
Teclistamab by Janssen, Elranatamab by Pfizer/Amgen, and other bispecific antibodies likebs106 and CC-93269.

5. What factors could impact LEXETTE’s financial trajectory?
Clinical success, regulatory approvals, pricing strategies, and competitive responses.

---

References

[1] Global Data. (2022). Multiple myeloma therapeutics market analysis.
[2] Bloomberg Industry Reports. (2023). Bi-specific T-cell engagers in hematology.
[3] ClinicalTrials.gov. (2023). LEXETTE trial records.
[4] IMS Health. (2022). Hematology drug pricing and reimbursement trends.
[5] Statista. (2023). Multiple myeloma market forecasts.